drugset / Trial / NCT00002862

Perillyl Alcohol in Treating Patients With Refractory Cancer

NCT00002862 ↗

Phase 1 Completed 25 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of perillyl alcohol in treating patients with refractory cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start
1996-10
Primary completion
2001-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject perillyl alcohol Small molecule — Oral

Indications